Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Icf004

Phase 1

RRuijin Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Interstitial Lung Disease (ILD)Not yet recruiting

Interstitial Lung Disease (ILD)Phase 1

Not yet recruiting

Timeline

Expected Milestones

Q3 2029

Phase 1Not yet recruiting

Interstitial Lung Disease (ILD)

NCT07719218

Clinical

Trials by Indication[1]

Interstitial Lung Disease (ILD)1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of ICF004 in Healthy Chinese Participants

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07719218·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Icf004. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Icf004. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRuijin Hospital

Related News